Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Late-season Influenza Vaccine Responses 2023 vs 2024
NCT06567860Phase 4Completed
- Sponsor
- La Jolla Institute for Immunology
- Start
- May 2024
- Primary completion
- Feb 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Fluzone Trivalent in Influenza A (IAV), sponsored by La Jolla Institute for Immunology. Primary endpoints: Magnitude of Antibody Response After the Late-season 2023 Vaccine at 90 days and Magnitude of the Antibody Response After the 2024 Vaccine at 90 days. Started May 2024; status: completed.
02
Drugs
Fluzone Trivalent
03
Conditions
Influenza A (IAV)
Beyond the preview
Go deeper on NCT06567860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06567860.